Table 3.
Ongoing trials on systemic treatment of brain metastases from NSCLC.
| Study Name | Target | Phase | Trial |
|---|---|---|---|
| Targeted therapy | |||
| Study of Osimertinib + SRS vs. Osimertinib Alone for Brain Metastases in EGFR-Positive Patients With NSCLC | EGFR | Phase II | NCT03769103 |
| Keynatinib in Treated Patients With NSCLC and Brain Metastases | EGFR | Phase II | NCT04824079 |
| A Randomised Phase II Trial of Osimertinib With or Without SRS for EGFR Mutated NSCLC With Brain Metastases (OUTRUN) | EGFR | Phase II | NCT03497767 |
| A Phase I/II Study of AMG 510 in Combination With MVASI in Patients With Advanced, Unresectable or Metastatic KRAS G12C Mutant NSCLC With Asymptomatic Brain Metastasis | KRASG12C VEGF |
Phase I Phase II |
NCT05180422 |
| Study of TY-9591 in Patients With a Lung Cancer With Brain or Leptomeningeal Metastases With EGFR Mutation | EGFR | Phase II | NCT05146219 |
| Neurocognition in NSCLC Patients Treated With Osimertinib or Osimertinib + WBI | EGFR | Phase II | NCT04829019 |
| Almonertinib Combined With Cerebral Radiation Treat Brain Metastases From EGFR-Positive NSCLC | EGFR | Phase II | NCT04905550 |
| Immunotherapy | |||
| Nivolumab and Ipilimumab Plus Chemotherapy for Patients With Stage IV Lung Cancer With Brain Metastases (NIVIPI-Brain) | CTLA-4 PD-1 |
Phase II | NCT05012254 |
| Pembrolizumab Plus Bevacizumab for Treatment of Brain Metastases in Metastatic Melanoma or Non-small Cell Lung Cancer | PD-L1 VEGF |
Phase II | NCT02681549 |
| Phase II Investigation of Use of CNS Active Pembrolizumab and Chemotherapy for Asymptomatic Brain Metastasis From Non-small Cell Lung Cancer (NSCLC) | PD-L1 | Phase II | NCT04964960 |
| Toripalimab Combined With Anlotinib and SBRT in Patients With Untreated Brain Metastases of Driven Gene-negative NSCLC | Non-driver-related brain metastasis | Phase I | NCT05021328 |
| LITT and Pembrolizumab in Recurrent Brain Metastasis (TORCH) | Recurrent brain metastasis with failed radiosurgery | Phase I | NCT04187872 |